产前暴露于选择性5-羟色胺再摄取抑制剂与儿童脑肠互动障碍风险
基于丹麦1997-2015年出生的1,158,560名单胎儿童登记数据,比较孕期继续使用SSRI与孕前已停用SSRI母亲所生子女,随访至15岁、结局发生、死亡、移民或2018年12月。产前SSRI暴露儿童总体脑肠互动障碍风险轻度升高(HR 1.08,95%CI 1.02-1.14),主要由功能性便秘驱动(HR 1.19,95%CI 1.10-1.28)。
要点
- 产前SSRI暴露儿童总体脑肠互动障碍风险轻度升高,HR为1.08(95%CI 1.02-1.14)。
- 风险升高主要由功能性便秘驱动,其HR为1.19(95%CI 1.10-1.28)。
- 功能性恶心呕吐与功能性腹痛障碍未见风险升高。
核心结论
- 产前SSRI暴露与儿童功能性便秘风险升高相关,这些发现与支持5-羟色胺在肠道发育和功能中起关键作用的广泛临床前数据一致。
- 研究结果支持需进一步探究母亲抑郁及SSRI暴露对常见胃肠道疾病发育的长期影响。
研究设计与样本
- 基于人群登记资料的队列研究,纳入1997-2015年出生的全部丹麦单胎儿童,随访至结局发生、15岁、死亡、移民或2018年12月。
- 共纳入1,158,560名儿童,其中21,969名(1.9%)产前暴露于SSRI,30,174名(2.6%)的母亲在孕前已停用SSRI。
- 采用Cox回归比较孕期继续使用SSRI母亲所生子女与孕前停用SSRI母亲所生子女。
- 主要结局为儿童期脑肠互动障碍(功能性恶心呕吐、功能性腹痛障碍、功能性腹泻、功能性便秘)首次诊断或医生处方泻药。
主要发现
- 任何脑肠互动障碍的15年累积发生率在SSRI暴露组为15.5%(95%CI 14.9-16.2),在未暴露组为14.7%(95%CI 14.0-15.3)。
- SSRI暴露儿童总体脑肠互动障碍风险升高(HR 1.08,95%CI 1.02-1.14)。
- 风险升高由功能性便秘驱动(HR 1.19,95%CI 1.10-1.28)。
- 功能性恶心呕吐未见风险升高(HR 0.97,95%CI 0.83-1.13);功能性腹痛障碍未见风险升高(HR 0.90,95%CI 0.81-1.00)。
关键数值与推荐
- 主要结局为儿童期脑肠互动障碍首次诊断,包括功能性恶心呕吐、功能性腹痛障碍、功能性腹泻和功能性便秘,或医生处方泻药。
- 比较组为孕期继续使用SSRI母亲所生子女与孕前停用SSRI母亲所生子女。
- 随访终止条件为结局发生、15岁、死亡、移民或2018年12月。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出需进一步探究母亲抑郁及SSRI暴露对常见胃肠道疾病发育的长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical data suggest that gestational exposure to selective serotonin reuptake inhibitors (SSRI) alter gut innervation, and delays colonic motility. In this study we investigated associations between gestational SSRI exposure and offspring disorders of gut-brain interaction (DGBI). Using population-based registries, we included all single-birth Danish children born 1997-2015 with follow-up until outcome occurrence, age 15 years, death, emigration, or December 2018. Children to mothers who continued SSRIs during pregnancy and children to mothers who discontinued SSRI use before pregnancy were compared using Cox regression. Main outcomes were the first diagnosis of a childhood DGBI (functional nausea and vomiting, functional abdominal pain disorders, functional diarrhea, and functional constipation), or a physician-prescribed laxative. Among 1,158,560 children, 21,969 children (1.9%) were exposed to SSRIs prenatally and 30,174 children (2.6%) were born to mothers who discontinued SSRIs before pregnancy. Overall, the estimated 15-year cumulative incidence of any DGBI was 15.5% (95% CI, 14.9-16.2) in the SSRI-exposed group and 14.7% (14.0-15.3) in the unexposed group. SSRI-exposed children had an overall increased risk of DGBIs (HR 1.08, [1.02-1.14]), which was driven by functional constipation (HR 1.19, [1.10-1.28]) rather than functional nausea and vomiting (HR 0.97, [0.83-1.13]) or functional abdominal pain disorders (HR 0.90, [0.81-1.00]). These data suggest that prenatal SSRI exposure is associated with an increased risk of developing functional constipation. These findings are also consistent with extensive preclinical data supporting key roles for serotonin in gut development and function. Together findings support the need for further investigation of the long-term impact of maternal depression and SSRI exposure on development of common gastrointestinal disorders.
引用
- Kildegaard H, Bliddal M, Ernst MT, et al. Prenatal exposure to selective serotonin reuptake inhibitors and risk of disorders of gut-brain interaction in children. Mol Psychiatry. 2024. PMID: 39658704. doi:10.1038/s41380-024-02848-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。